Bis-(hydroxylakylamino)-anthraquinone inhibitors of protein kina

Details Bis-(hydroxylakylamino)-anthraquinone inhibitors of protein kina Bis-(hydroxylakylamino)-anthraquinone inhibitors of protein kina

1992-06-08

1994-09-06

Ivy, C. Warren

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514471, 514510, 514541, 514564, 514618, 514620, 514637, A01N 4710, A01N 4316

Patent

active

053448413

ABSTRACT:
##STR1## The present invention provides novel substituted anthraquinones having formula (.alpha.), wherein R.sub.1 and R.sub.2 are independently H, C.sub.1 -C.sub.10 alkyl, aryl, arylalkyl, alkylaryl, or R.sub.1 and R.sub.2 taken together with the adjacent nitrogen atom N form a substituted or unsubstituted cyclic ring which may contain additional heteroatoms; n and m are independently 1, 2, or 3; A is halogen, OH, alkoxy, OCO(NR.sub.3 R.sub.4), S--C(NH.sub.2)=NR.sub.5, or when m=1, comprises an oxirane ring with the adjacent oxygen atom; R.sub.3, R.sub.4, and R.sub.5 are independently H, alkyl, or aryl; X is H, OH, NR.sub.6 R.sub.7, Cl, Br, I, F, alkyl, aryl, alkoxy, aryloxy, COOR.sub.8, or CONR.sub.9 R.sub.10 ; and R.sub.6, R.sub.7, R.sub.8, R.sub.9, and R.sub.10 are independently H, lower alkyl, or aryl useful for inhibiting protein kinase C and treating conditions related to, or affected by inhibition of protein kinase C, particularly cancer tumors, inflammatory disease, reperfusion injury, and cardiac dysfunctions related to reperfusion injury.

REFERENCES:
patent: 1540733 (1925-06-01), Baddiley et al.
patent: 2411148 (1946-11-01), Dickey et al.
patent: 3960751 (1976-06-01), Moriyama et al.
patent: 4197249 (1980-04-01), Murdock et al.
patent: 4310666 (1982-01-01), Zee-Cheng et al.
patent: 4526989 (1985-07-01), Murdock et al.
patent: 4540788 (1985-09-01), Murdock
patent: 4598155 (1976-07-01), Adam
patent: 4762648 (1988-08-01), Stache et al.
patent: 4816450 (1989-03-01), Bell et al.
patent: 4894451 (1990-01-01), Krapcho et al.
Castagna et al. (1982), J. Biol. Chem. 257:7847.
Grunicke et al. (1989), Adv. Enzyme Regul. 28:291.
Tritton, T. R., et al., Cancer Cells 2:95-102 (1990).
Schactele et al. (1988) Biochem. Biophy. Res. Commun. 151:542.
Hannun et al., (1987), J. Biol. Chem. 262:13620.
Yamada et al. (1988), Biochem. Pharmacol. 37:1161.
McIntyre et al. (1987), J. Biol. Chem. 262:15730.
Lambreth et al. (1988) J. Biol. Chem. 263:3818.
Pittet et al. (1987), J. Biol. Chem. 262:10072.
Gaudry et al. (1988), Immunology 63:715.
Wilson et al. (1986), J. Biol Chem. 261:12616.
Fujita et al. (1986) Biochem. Pharmacol. 35:4555.
Berkow et al. (1987), J. Leukoc., Biol. 41:441.
Salzer et al. (1987), Biochem. Biophys. Res. Commun. 148:747.
Kramer et al. (1989), J. Biol. Chem. 262:5876.
Dewald et al. (1989), Biochem. J. 264:879.
Kocovsky et al. (1986), Tetrahedron Letters 27:5521.

Affiliated with

Also associated with

Rating

Bis-(hydroxylakylamino)-anthraquinone inhibitors of protein kina does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bis-(hydroxylakylamino)-anthraquinone inhibitors of protein kina, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bis-(hydroxylakylamino)-anthraquinone inhibitors of protein kina will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1329673